

Registration Form

Please mail or fax to:
Susanna Blüml
Dept. of Hematology and Oncology
University of Regensburg
F.J. Strauss Allee 11, 93053 Regensburg, Germany
Phone: -49-941-944-5542
Fax: -49-941-944-5543
e-mail: Susanna.Blueml@klinik.uni-regensburg.de

Consensus Conference on Clinical Practice in Chronic GVHD Regensburg

November 6 to 7, 2009

- I want to participate at the consensus conference
- I want to participate at the first line treatment session (on Friday)
- I want to participate at the second line treatment session (on Friday)
- I want to participate at the supportive care session (on Friday)
- I will not be able to participate at the consensus conference
- I need support with hotel reservation

Address:

Name: _____

Institution: _____

Address: _____

e-mail: _____

Phone: _____

Fax: _____

Conference Venue

Hörsaal A 2
University Hospital Regensburg
Franz-Josef-Strauss-Allee 11
93053 Regensburg, Germany

Parallel Seminars
A2, 1. Floor, Room 4.04 und 4.05

General tourist and hotel information

Tourist-Information Altes Rathaus
Rathausplatz 4
93047 Regensburg
Germany
Tel.: +49-(0)941/507-4410
Tel.: +49-(0)941/507-4411
<http://www.tourismus.regensburg.de/tourismus/de/medienportal/1160>

Local Contact

PD Dr. Daniel Wolff
Dept. of Hematology and Oncology
University Hospital Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg

Tel.: +49- (0)941/944-5531
Fax: +49- (0)941/944-5543
Email: daniel.wolff@klinik.uni-regensburg.de

Invited international participants:

Prof. G. Socie MD, PhD
Service d'Hematologie Greffe. & Inserm U728
Hospital Saint-Louis, 1 Av. Vellefaux,
75010 Paris, France
e-mail: gerard.socie@sls.aphp.fr

Prof. Stephanie J. Lee, MD
Fred Hutchinson Cancer Research Center
1100 Fairview N
D5-290, Seattle, WA 98109
e-mail: sjlee@fhcrc.org

Prof. Steven Z. Pavletic, MD
Head of GVHD and Autoimmunity Unit
Experimental Transplantation and Immunology Branch
Center of Cancer Research
National Cancer Institute
10 Center Drive, CRC, Room 4-3130
Bethesda, MD 20892-1203
E-mail: pavletis@mail.nih.gov

Prof. Mohamad Mohty MD PhD
CHU de Nantes, Hematologie Clinique
Universite Nantes
Place A Ricordea
44093 Nantes Cedex, France
e-mail mohamad.mohty@univ-nantes.fr

Dr. Sharon Elad, DMD MSc
Head, Hospital Oral Medicine Service
Department of Oral Medicine
The Hebrew University-Hadassah School of Dental Medicine
POB 12272, Jerusalem 91120
e-mail: sharonela@ekmd.huji.ac.il

Supported by:



Dr. Falk Pharma GmbH
Roche Pharma AG,
Fresenius Biotech GmbH,
Essex Pharma GmbH
Amgen GmbH,
Alexion Pharma Germany GmbH
Bristol Myer Squibb GmbH,
Gilead Sciences GmbH
MSD Sharp & Dohme GmbH
Whyett Pharma GmbH
Novartis Pharma GmbH
Pfizer Pharma GmbH

Consensus Conference on Clinical Practice in Chronic GVHD Regensburg

November 6 to 7, 2009



Hörsaal A2

University Hospital of Regensburg

Department of Hematology & Oncology

Competence Center GVHD Regensburg

Organization:
Prof. Dr. E. Holler, PD Dr. D. Wolff, Prof. Dr. R. Andreesen

Dear colleagues,

we are pleased to invite you to the Consensus conference on Clinical Practice in chronic GVHD 2009 held in Regensburg. Chronic GVHD continues to be a challenge in clinical practice balancing GVHD treatment against toxicity and infectious morbidity. Furthermore chronic GVHD remains the leading cause of long term morbidity and mortality after hematopoietic stem cell transplantation. Despite of its clinical importance, progress in understanding of pathophysiology and treatment has been rather slow. More recently chronic GVHD has moved into focus of transplant physicians starting with the NIH headed consensus conference on chronic GVHD. While this has led to considerable progress in the quality of clinical trials, the current challenge is to improve diagnosis, severity grading and treatment in clinical routine. The 2009 consensus conference is aiming to develop feasible standards for diagnosis and severity grading of chronic GVHD and to provide guidelines for immunosuppressive as well as supportive treatment of chronic GVHD.

H. Greinix (Wien)
A. Lawitschka (Wien)
H. Bertz (Freiburg)
R. Schwerdtfeger (Wiesbaden)
E. Holler and D. Wolff (Regensburg)

Competence Center GVHD

supported by

Friday, November 6th

11.30 – 12.30 Lunch

- 12.30 – 13.30 Opening and Welcome Address**
12.30 – 12.40 Welcome (R. Andreesen)
12.40 – 12.55 NIH consensus on chronic GVHD – 4 years follow up (S. Pavletic)
12.55 – 13.30 Chronic GVHD – from bench to bedside (E. Holler)

- 13.30 – 15.30 Joint Session: Diagnosis and Staging of chronic GVHD**
(Chair: H. Greinix, S. Pavletic)
13.30 – 14.10 Diagnosis of cGVHD (H. Greinix)
14.10 – 14.30 Histology in diagnosis of cGVHD (C. Loddenkemper)
14.30 – 14.45 Diagnosis of ocular cGVHD (T. Dietrich)
14.45 – 15.10 Pediatric aspects on Diagnosis of cGVHD (A. Lawitschka)
15.10 – 15.30 Documentation of cGVHD in clinical routine (D. Wolff)

15.30 – 16.00 Coffee break

- 16.00 – 18.30 Meeting of the subcommittees**
First-Line and topical treatment of chronic GVHD
(Chair: D. Wolff, G. Socie)
16.00 – 16.30 Results of the survey on first line and topical treatment of cGVHD (D. Wolff)
16:30 – 16.50 Treatment of mild cGVHD – topical immunosuppression (D. Wolff)
16.50 – 17.10 Role of steroids and calcineurin inhibitors in first line treatment (F. Ayuk)
17.10 – 17.30 Role of MMF in first line treatment (A. Gerbitz)
17.30 – 18.10 Role of photopheresis in first line treatment (H.Greinix)
18.10 – 18.30 Special consideration in cGVHD with progressive onset / overlap syndrome (H. Greinix)

Second-Line treatment of chronic GVHD

(Chair: R. Schwerdtfeger, E. Holler, M. Mohty)

- 16.00 – 16.30 Results of the survey on second line treatment (R. Schwerdtfeger)
16.30 – 17.00 Principals of second line treatment of cGVHD (M. Schleuning)
17.00 – 17.30 mTOR Inhibitors in second line treatment (M. Schleuning)
17.30 – 17.45 Photopheresis in second line treatment (S. Harsdorf)

- 17.45 – 18.15 Role of Rituximab, Alefacept, Etanercept, Campath in second line treatment (G. Kobbe)
18.15 – 18.30 Role of MMF in second line treatment (A. Gerbitz)

Supportive Therapy

- (Chair: H. Bertz, S. Lee, S. Elad)
16.00 – 16.15 Supportive care in fasciitis (M. Stadler)
16.15 – 16.30 Supportive care of oral cGVHD (J. Meier)
16.30 – 16.45 Supportive care of ocular cGVHD (T. Dietrich / N. Basara)
16.45 – 17.00 Supportive care of gastrointestinal manifestations of cGVHD (K. Rieger)
17.00 – 17.15 Supportive care of gynecological manifestations of cGVHD (J. Halter)
17.15 – 17.30 Supportive care of neurological manifestations of cGVHD (I. Kleiter)
17.30 – 17.50 Infectious monitoring and prophylaxis (H. Bertz)
17.50 – 18.05 Psychosocial aspects (J. Weis / F. Mumm)
18.05 – 18.30 Paediatric aspects (A. Lawitschka)

Welcome reception

Location: Restaurant “Leerer Beutel”

Bertoldstr. 9, 93047 Regensburg,
www.leerer-beutel.de

Saturday, November 7th

Presentation of the Consensus

8.30 – 9.45

Diagnosis and Staging

- (Chair: H. Greinix, S. Pavletic)
Clinical and histological diagnosis of chronic GVHD (H. Greinix)
9.15 – 9.30 Paediatric aspects (A. Lawitschka)
9.30 – 9.45 Documentation of chronic GVHD in clinical routine (D. Wolff)

09.45 – 10.00

Coffee break

10.00 - 11.00

First Line Treatment

- (Chair: D. Wolff, G. Socie)
10.00 – 10.15 Role of steroids and calcineurin inhibitors in first line treatment (**F. Ayuk** / A. Kiani)
10.15 – 10.30 Role of MMF and photopheresis in first line treatment (**A. Gerbitz** / H. Greinix)
10.30 – 10.40 Special consideration in GVHD with progressive onset / overlap syndrome (H. Greinix)
10.40 – 11.00 Treatment of mild GVHD – topical immunosuppression (D. Wolff)

11.00 - 12.30

Second Line Treatment

- (Chair: R. Schwerdtfeger, E. Holler, M. Mohty)
11.00 – 11.10 Role of steroids and calcineurin inhibitors in second line treatment (F. Ayuk / **A. Kiani**)
11.10 – 11.30 Role of photopheresis, MMF and mTOR Inhibitors in second line treatment (E. Holler / S. von Harsdorf / A. Gerbitz / **M. Schleuning**)
11.30 – 11.45 Role of MTX, Cyclophosphamide, Pentostatine, Clofazimine (U. Bacher)
11.45 – 12.00 Role of Hydroxychloroquine, Thalidomide, Retinoids, total nodal irradiation, Imatinib (D. Wolff / M. Stadler / **R. Schwerdtfeger**)
12.00 – 12.15 Role of Rituximab, Alefacept, Campath, Etanercept (**G. Kobbe** / M. Gramatzki)
12.15 – 12.30 Paediatric aspects (A. Lawitschka)

12.30

Lunch

13.00 - 15.30

Supportive Therapy

- (Chair: H. Bertz, S. Lee, S. Elad)
13.00 – 13.30 Supportive care in skin, fascial, oral and gynecological manifestations of cGVHD (**C.L. Marks**, M. Stadler / J. Meier / J. Halter)
13.30 – 14.00 Supportive care of ocular, pulmonary and GI-manifestations of cGVHD (T. Dietrich / G. Hildebrandt / **K. Rieger**)
14.00 – 14.30 Monitoring and prophylaxis of infections, vaccination, immune cytopenias and other autoimmune syndromes (**H. Bertz** / A. Kiani / I. Hilgendorf)
14.30 – 14.50 Neurological manifestations of GVHD, osteoporosis and osteonecrosis (**E. Holler** / I. Kleitner / A. Hautmann)
14.50 – 15.05 Psychosocial aspects of cGVHD (A. Mumm, **F. Mumm**, J. Weis)
15.05 – 15.30 Paediatric aspects (growth, hormone replacement (**A. Lawitschka**))

15.30 – 16.00

Conclusion

(E. Holler, S. Pavletic, H. Bertz, M. Mohty, G. Socie, D. Wolff, S. Lee)